Employees Archives - Page 4 of 5 - Juvena Therapeutics

Peter Jackson, PhD

Peter Jackson is a Professor in the Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, at the Stanford University School of Medicine. Dr. Jackson returned to Stanford in 2013 after eight years as a Staff Scientist and Director at Genentech Inc. in S. San Francisco, California. At Genentech, he helped define and implement the development of therapeutics for cancer pathways including cell cycle checkpoints, stress pathways, and tumor metabolism. Before joining Genentech in 2005, he spent 10 years on the faculty at Stanford University School of Medicine. His laboratory has been involved in studies of cell cycle biochemistry, regulation of the cancer by kinases and phosphatases, the ubiquitin-proteasome system, and the discovery of a new physiological class of competitive (“pseudosubstrate”) E3 ubiquitin ligase inhibitors, exemplified by the APC/C regulator Emi1.

Since 2005, his lab has focused on signaling through the primary cilium, using proteomic approaches to define regulatory networks and new disease genes. More broadly, the lab has connected many proteins defective in human diseases and cancer to new complexes and pathways, with a view to discovering molecular signatures for diagnostics and therapeutic development. His research has earned him numerous visiting lectureships and honors, including awards from the Baxter Foundation, Howard Hughes Medical Institute, the American Cancer Society, the Pluto Society, and being a Stanford Hume Faculty Scholar and a Kirsch Scholar, and elected a Fellow of the American Association for the Advancement of Science (in 2008).

Learn more about Peter

LinkedIn
Stanford School of Medicine

Back to Careers

Jeff Welch

Jeff Welch has over 30 years of CMC experience in the process development, GMP manufacturing and facilities, and regulatory documentation.

In Jeff’s most recent role as a consultant he has had responsibility for authoring and reviewing regulatory filing sections related to process development and product characterization.

Over the past decade Jeff has focused on his role as a senior director for drug substance (DS) process development and director over process engineering and operations for a specialty pharmaceutical company working in biologics and vaccines and as a CDMO organization.

Jeff has also served as a project manager for large scale manufacturing and technology transfer projects and filled the DS team leader role. After a lead role in engineering and construction, he served as a senior manager over the start up effort for a stainless steel cell culture facility (1600 L scale), where he hired and managed personnel and led a 7-day-a-week cGMP manufacturing operation for the upstream portion.

In his early career he participated in design of a multi-product manufacturing facility and after start-up performed process fit and technology transfer activities for several microbial, yeast and cell culture products.

Learn more about Jeff Welch

Back to Careers

Shari-Anne Burgess, RN

Shari Burgess brings over 25 years of clinical experience to the life science and healthcare industry working in a variety of indications such as but not limited to oncology, neuromuscular disorders, rare disease, regenerative medicine, burn and wound care and orthopedics. She is the Chief Clinical Operations Lead in her clinical consulting company, Clinsytes Inc., a niche clinical consulting company that provides global clinical operation insights and solutions for small to midsize life science companies for the improvement of clinical operational performance and delivery of measurables in drug/device development, trial management and business development strategies. Previous to Clinsytes, Shari held senior management roles at CROs and medical/biotech companies.

Learn more about Shari-Anne

LinkedIn

Back to Careers

Elizabeth Neyens, PhD

With 20 years of experience as a Board-certified toxicological pathologist and a DVM, Dr. Elizabeth Neyens has dedicated their career to advancing drug development. They began as a staff pathologist at Merck and Charles River Preclinical Drug Development, followed by serving as Head of Pathology at Baxter in Europe. During a pivotal year in Israel, she worked as a consultant, supporting an IPO transition, before returning to North America to become a Professor of Pathology at Einstein Medical University in New York.

A recognized expert in biologics, Elizabeth played a advisory role in guiding the preclinical pipeline for JUV-161. Her professional focus lies in delivering GLP-compliant preclinical development programs, conducting peer reviews, and supporting successful IND submissions. Driven by a passion for translating innovative molecules into clinical success, they are committed to making global healthcare advancements accessible to patients worldwide.

Learn more about Elizabeth

Back to Careers

Sarah Tang

Sarah joined Juvena Therapeutics as a Senior Research Associate to contribute to protein expression and assay optimization. She obtained her bachelor’s degree in molecular and cell biology from the University of California, Berkeley.

Before joining Juvena Therapeutics, Sarah worked as a Research Associate in the antibody discovery field, where she attained hybridoma sequences, antibody transient expression, and hit identification. Prior to transitioning to research, Sarah worked in the clinical diagnostics field as a Lab Administrative Manager. She managed lab operations while staying active on the bench.

In Sarah’s free time, she enjoys creating content for her cat’s social media, gaming with friends, and attending ballet performances.

Learn more about Sarah

Back to Careers

Megan Smith

Megan brings eight years of industry experience in mammalian cell culture, protein expression, and protein purification. She holds a Bachelor’s degree in Cell and Molecular Biology from California State University, Eastbay. Prior to joining Juvena Therapeutics, Megan worked as an Associate Scientist in the Protein Sciences group at Bristol Myers Squibb. In this position, she played a crucial role in producing various protein modalities in support of R&D efforts across a wide range of biological targets. Outside of work, Megan enjoys puzzles, art, and volunteering at Nine Lives Cat Rescue.

Learn more about Megan

Back to Careers

Annie Yang, MS

Annie joined Juvena Therapeutics as a research associate II working on preclinical in vivo and in vitro disease modeling and drug discovery.

She received her master’s degree in Biomedical Engineering from the University of Southern California. During her time as a graduate student, Annie participated as a research volunteer in an immunology group. Her project focused on investigating the influence of the coronavirus envelope protein on CD1d expression. This experience provided her with valuable training in fundamental molecular techniques, such as genotyping, flow cytometry, western blotting, and conducting in vivo experiments.

Before joining Juvena, Annie worked as a Research Associate in the field of toxicology at Sorrento Therapeutics for one year. In this position, she played a crucial role in supporting the toxicity team, particularly in the tissue cross-reactivity assay. Her responsibilities included performing histological procedures such as embedding and sectioning both paraffin and frozen tissues, conducting H&E staining, IHC, IF, and acquiring images.

During her free time, Annie finds joy in activities such as jogging, hiking, and gaming with her friends.

Learn more about Annie

Back to Careers

Susan Molineaux, PhD

Dr. Molineaux has been the Chief Executive Officer at Para Therapeutics, Inc., since April 2023. Previously, she was Chief Executive Officer, President and a member of the board of directors of Calithera Biosciences, Inc., since co-founding the company in June 2010 until March 2023.

Dr. Molineaux has served as a member of the board of directors of the Geron Corporation since 2012, Repare Therapeutics since April 2023, Cyteir Therapeutics, Inc., a clinical-stage DNA repair and synthetic lethality company, from December 2020 until May 2023, and Theravance Biopharma, Inc., a biopharmaceutical company, from April 2015 to April 2022. She has also been a Scientific Advisor to Lightstone Ventures, a private life sciences investment company, since September 2016. Dr. Molineaux co-founded Proteolix, Inc., a privately held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009, until the company’s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009.

Previously, Dr. Molineaux held several senior management positions in the biopharmaceutical industry, including Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases, Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular biology from Johns Hopkins University and completed a postdoctoral fellowship at Columbia University.

Learn more about Susan

LinkedIn

Back to Careers

Theodore Yu

Theodore Yu joined Juvena Therapeutics as a research associate contributing to protein production and in-vitro assay development. Theodore earned his undergraduate degree in biology, with a minor in chemistry, from San Jose State University. During his time at SJSU, he served as an undergraduate research assistant in the Payumo Lab, focused on cardiac regenerative biology. Theodore’s role investigated molecular and cellular processes regulating cardiomyocyte cell cycle regulation, through molecular cloning techniques and IHC staining. Outside of work, Ted enjoys spending time with his family, friends, and cat. He also finds joy in taking scenic drives through the hills.

Learn more about Theodore

Back to Careers

Louis J. Aronne, MD, FACP, DABOM

Dr. Louis Aronne is a leading authority on obesity and its treatment. He is the Sanford I. Weill Professor of Metabolic Research and the director of the Comprehensive Weight Control Center in the division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medicine in New York City. A graduate of Johns
Hopkins University School of Medicine, Dr. Aronne is a founder and past chairman of the American Board of Obesity Medicine and a past president of The Obesity Society. He is a founder and Executive Chairman of Intellihealth, a cloud-based weight management system for healthcare providers.

He completed his internship and residency at Albert Einstein College of Medicine and Jacobi Medical Center, followed by a Henry J. Kaiser Family Foundation Fellowship in General Internal Medicine at New York-Presbyterian/Weill Cornell Medical Center.

Dr Lingvay is an active member of the American Diabetes Association, where she has served over the years on several committees, including the Organizing Committee for the Annual Scientific Sessions, Focus on Fellows Advisory Board, WIN-ADA Advisory Board, Grant Review Committee, and the Professional Practice Committee. She is on the Editorial Board of several journals, including Diabetes Care. She participated in nearly 100 clinical trials and has a special interest in cardiovascular outcome trials and obesity trials. She authored over 160 publications in major medical journals and authored chapters in several popular diabetes textbooks.

Learn more about Louis

LinkedIn